Back to search results
NCT07179042

Intertrochanteric Femur Fracture Patients Who Receive Metformin With a Placebo

Enrolling by Invitation
EARLY_PHASE1Ages 60–90InterventionalTreatment
University of Utah
~60 participants
Updated 2026-04-29 on ClinicalTrials.gov
What's tested:PlaceboMetformin

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Mid-thigh size (MTS), (centimeters)
Measured over 2-weeks after surgery
+2 more outcomes measured

Conditions

Intertrochanteric Femur Fracture
Muscle Atrophy

Explore related trials

Fracture of neck of femurIntertrochanteric fractureSubtrochanteric fracture of femur

Where it's being run

1 sites across 1 states
Utah1

Study leadership

  • Justin Haller, M.D. · PRINCIPAL_INVESTIGATOR · University of Utah Orthopaedics

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 60y and older.
Displaced hip fracture (femoral neck, intertrochanteric femur, subtrochanteric femur fracture).
Low energy mechanism of injury (ground level fall, etc).
Operative treatment within 72 hours of injury.
Previously ambulatory.

Exclusion

History of kidney disease or failure (CKD \> stage 4; eGFR \< 45 mL/min/1.73m2).
History of diabetes mellitus (HbA1c \> 6.5).
Associated lower extremity fracture (ipsilateral or contralateral).
Pathologic fracture.
Presence of infection at the fracture site.
History of metabolic bone disease (Pagets, etc.).
Severe cognitive impairment (Six Item Screener with 3 or more errors).
Stage 5 Parkinson's Disease.
Open fracture.
Risk of developing metformin-associated hypoglycemia (e.g., hepatic impairment (by history or screening laboratory assessment), presence of hypoglycemia at screening, history of adrenal or pituitary insufficiency, alcohol use disorder, subjects unable to maintain normal oral intake).
Severe hepatic impairment (Child-Pugh C).
Expected survival \< 6 months (based on clinical judgement).

What this trial measures

  • Mid-thigh size (MTS), (centimeters)2-weeks after surgery

    Mid-thigh circumference will be assessed in the participants. These tests will occur during the standard clinical follow-up visits at 2, 8, and 16 weeks. Each participant will have both legs assessed.

  • Mid-thigh size (MTS), (centimeters)8-weeks after surgery

    Mid-thigh circumference will be assessed in the participants. These tests will occur during the standard clinical follow-up visits at 2, 8, and 16 weeks. Each participant will have both legs assessed.

  • Mid-thigh size (MTS), (centimeters)16-weeks after surgery

    Mid-thigh circumference will be assessed in the participants. These tests will occur during the standard clinical follow-up visits at 2, 8, and 16 weeks. Each participant will have both legs assessed.